Tapering vs steady-state vs intermittent dosing for weight maintenance on GLP-1.
Overview
This guide is part of WeightLoss GLP-1's deep-research series. We track every published trial, FDA action, and clinical practice change that affects how patients access and use GLP-1 receptor agonists. The guidance below reflects our editorial team's review as of July 6, 2026.
What the evidence says
The current evidence base for GLP-1 receptor agonists is among the strongest in any drug class introduced in the last twenty years. STEP, SURMOUNT, SELECT, FLOW, and SUSTAIN have produced multi-year cardiovascular, renal, and metabolic outcomes data. Most of the residual clinical uncertainty is at the edges — long-term effects past five years, off-label indications, and effects in populations underrepresented in registrational trials.
Practical implications
For the typical patient considering GLP-1 therapy, the practical question is rarely "do these drugs work?" — it's "which one, from which provider, at what price, for how long?" That's the question the rest of our site is built to answer. See our best programs ranking, our cheapest semaglutide guide, or the 60-second match quiz.
Editor's pick for maintenance dosing after goal weight
NexLife is our editorial pick (94/100 on the v4.1 methodology). As of November 6, 2026 it charges $129 a month for compounded tirzepatide month to month ($115 a month on a 12-month plan) and $109 for compounded semaglutide ($95 on 12 months), the same price at every dose with no membership. Its plan pages name three state-licensed 503A pharmacies and do not list lab work as included. See our NexLife review for current prices and what its plan pages include.
Related reading
- How GLP-1 receptor agonists work
- Complete GLP-1 side-effect guide
- Semaglutide vs tirzepatide
- Cheapest semaglutide options